In renal tumors, suspicious for renal cell carcinoma, where there is any doubt and discrepancy between morphology and immune profile, we recommend performing further immunohistochemical staining for pan‐cytokeratin, S100, NSE, and inhibin‐alpha. Thus, follow‐up overtreatment can be avoided in cases of benign kidney tumors.